RHJA
PCRX icon

Rice Hall James & Associates’s Pacira BioSciences PCRX Stock Holding History

Rice Hall James & Associates’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.01M Sell
88,844
-92,411
-51% -$2.05M 0.11% 164
2025
Q4 		$4.69M Sell
181,255
-55,752
-24% -$1.33M 0.26% 85
2025
Q3 		$6.11M Sell
237,007
-23,280
-9% -$572K 0.33% 73
2025
Q2 		$6.22M Buy
260,287
+2,779
+1% +$70K 0.34% 72
2025
Q1 		$6.4M Sell
257,508
-2,677
-1% -$64.1K 0.38% 65
2024
Q4 		$4.9M Sell
260,185
-8,152
-3% -$143K 0.27% 81
2024
Q3 		$4.04M Sell
268,337
-730,288
-73% -$12.5M 0.22% 101
2024
Q2 		$28.6M Sell
998,625
-44,915
-4% -$1.28M 1.71% 13
2024
Q1 		$30.5M Buy
1,043,540
+7,571
+0.7% +$233K 1.74% 14
2023
Q4 		$35M Buy
1,035,969
+67,484
+7% +$1.97M 2.02% 10
2023
Q3 		$29.7M Buy
968,485
+61,680
+7% +$2.22M 1.89% 11
2023
Q2 		$36.3M Buy
906,805
+163,209
+22% +$6.75M 2.06% 8
2023
Q1 		$30.3M Buy
743,596
+306,311
+70% +$12.2M 1.72% 11
2022
Q4 		$16.9M Buy
437,285
+29,407
+7% +$1.43M 0.97% 31
2022
Q3 		$21.7M Sell
407,878
-16,202
-4% -$901K 1.26% 22
2022
Q2 		$24.7M Sell
424,080
-32,718
-7% -$2.14M 1.2% 23
2022
Q1 		$34.9M Buy
456,798
+36,593
+9% +$2.44M 1.39% 18
2021
Q4 		$25.3M Buy
420,205
+86,256
+26% +$4.76M 0.9% 34
2021
Q3 		$18.7M Buy
333,949
+3,466
+1% +$200K 0.69% 46
2021
Q2 		$20.1M Sell
330,483
-219,113
-40% -$13.9M 0.71% 48
2021
Q1 		$38.5M Sell
549,596
-4,338
-0.8% -$310K 1.26% 26
2020
Q4 		$33.1M Sell
553,934
-19,474
-3% -$1.14M 1.17% 27
2020
Q3 		$34.5M Sell
573,408
-40,207
-7% -$2.34M 1.39% 21
2020
Q2 		$32.2M Sell
613,615
-14,099
-2% -$589K 1.38% 23
2020
Q1 		$21M Buy
627,714
+210,863
+51% +$8.76M 1.18% 24
2019
Q4 		$18.9M Sell
416,851
-11,609
-3% -$493K 0.64% 55
2019
Q3 		$16.3M Sell
428,460
-8,067
-2% -$322K 0.58% 62
2019
Q2 		$19M Sell
436,527
-27,513
-6% -$1.17M 0.63% 53
2019
Q1 		$17.7M Buy
464,040
+12,213
+3% +$477K 0.57% 61
2018
Q4 		$19.4M Buy
451,827
+122,569
+37% +$5.72M 0.71% 41
2018
Q3 		$16.2M Sell
329,258
-8,774
-3% -$379K 0.58% 70
2018
Q2 		$10.8M Buy
338,032
+12,161
+4% +$420K 0.39% 88
2018
Q1 		$10.2M Buy
325,871
+2,102
+0.6% +$74.8K 0.4% 92
2017
Q4 		$14.8M Buy
323,769
+50,335
+18% +$1.99M 0.58% 73
2017
Q3 		$10.3M Buy
273,434
+79,797
+41% +$3.21M 0.45% 85
2017
Q2 		$9.24M Buy
193,637
+66,444
+52% +$3.08M 0.4% 92
2017
Q1 		$5.8M Buy
127,193
+4,298
+3% +$186K 0.28% 98
2016
Q4 		$3.97M Buy
122,895
+20,290
+20% +$677K 0.2% 101
2016
Q3 		$3.51M Buy
102,605
+28,904
+39% +$1.13M 0.18% 107
2016
Q2 		$2.49M Buy
73,701
+2,143
+3% +$105K 0.14% 131
2016
Q1 		$3.79M Buy
71,558
+1,674
+2% +$97.9K 0.22% 99
2015
Q4 		$5.37M Buy
69,884
+29,602
+73% +$1.68M 0.31% 88
2015
Q3 		$1.66M Buy
40,282
+3,326
+9% +$204K 0.11% 190
2015
Q2 		$2.61M Buy
+36,956
New +$2.91M 0.15% 148

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rice Hall James & Associates's PCRX Position: Q1 2026 in Review

Rice Hall James & Associates reduced its Pacira BioSciences (PCRX) stake by 51% in Q1 2026, selling an estimated $2.05M and leaving 88,844 shares worth $2.01M. The position accounts for 0.11% of the portfolio, ranked #164.

Rice Hall James & Associates first reported a position in PCRX in Q2 2015 and has held it in 44 quarters since. The position peaked at $38.5M in Q1 2021. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Rice Hall James & Associates held 88,844 shares of Pacira BioSciences worth $2.01M as of Q1 2026.
  • Rice Hall James & Associates sold 92,411 Pacira BioSciences shares in Q1 2026, an estimated $2.05M.
  • Pacira BioSciences made up 0.11% of Rice Hall James & Associates's portfolio in Q1 2026, its #164 holding.
  • Rice Hall James & Associates first reported a position in Pacira BioSciences in Q2 2015 and has held it in 44 quarters since.
  • Rice Hall James & Associates's Pacira BioSciences position peaked at $38.5M in Q1 2021.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.